In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Through the Palace Walls: Blood-Brain Barrier Transport Technologies

This article was originally published in Start Up

Executive Summary

Delivering compounds across the blood-brain barrier remains the rate limiting step in brain-drug development, yet the problem generally gets ignored until it's too late. Several biotechs are bringing novel strategies to finding a solution, focusing especially on brain cancers. Success may open the floodgates of CNS drug development.

You may also be interested in...



In ArmaGen, Investors Seek A Brain-Penetrating Breakthrough

For years, traditional VCs passed on ArmaGen’s technology that pulls drugs across the blood-brain barrier to reach previously undruggable targets. But in 2012, a syndicate of corporate investors obliged, suggesting they don’t mind losing their money if they can learn more about a difficult problem.

With Geron Deal Done, AngioChem Turns To Its Own Pipeline

A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.

With Geron Deal Done, AngioChem Turns To Its Own Pipeline

A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091818

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel